 DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept, 15, 2021 PRNewswire -- Theravance Biopharma, Inc. Theravance Biopharma or the Company NASDAQ: TBPH, a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from a Phase 3 randomized, double-blind, placebo-controlled multi-center Phase 3 study assessing the safety and efficacy of ampreloxetine compared to placebo for the treatment of symptomatic neurogenic orthostatic hypotension nOH. 